Últimas noticias sobre Petros Pharma (NASDAQ:PTPI) Bolsa

Petros Pharmaceuticals

Petros Pharmaceuticals Inc is a men's health pharmaceutical company. It focuses on therapeutics that promote medication adherence, tolerability, and preservation of male organic function. The company's operating segment includes Prescription Medications and Medical Devices. It generates maximum revenue from the Medical Devices segment. The Prescription Medications segment consists of operations related to vacuum erection devices, which are sold domestically and internationally.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AEMD

APCX

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

DALN

DSGN

ELAB

KULR

LITM

MESO

NVNI

PTPI

QNTM

SGMO

SLXN

VRAX

Acciones de Sangamo Therapeutics suben un 19,5% tras un nuevo acuerdo. Descubre los mayores ganadores y perdedores de hoy.

Acciones de Sangamo Therapeutics (SGMO) suben alrededor de un 20%; 20 acciones que se mueven en el premercado

Earnings

APDN

AUID

CERO

COMM

CRVS

EFSH

FSBW

NIVF

NUKK

PRTG

PRZO

RZLV

SHLT

SSBK

TNXP

VSTE

Acciones de Corvus suben un 22,5% pre-market tras anunciar datos de Soquelitinib. Descubre más ganadores y perdedores.

Acciones de Corvus Pharmaceuticals (CRVS) suben alrededor del 22%; 20 acciones que se mueven en premercado

Petros Pharmaceuticals, Inc. - Common Stock

Petros Pharmaceuticals Inc

PT CHANDRA ASRI PACIFIC by PT Chandra Asri Pacific Tbk

PT Chandra Asri Pacific Tbk

Wipro Ltd&nbsp;&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WIT#NYSE">WIT</a>) reported <a href="https://in.benzinga.com/topic/wipro" target="_blank" rel="noreferrer noopener">third-quarter gross revenue</a> of 223.2 billion rupees ($2.61 billion), up by 0.5% year-on-year, missing the&nbsp;analyst consensus estimate of&nbsp;$2.60 billion.&nbsp;
IT Services revenue declined by 1.0% Y/Y to $2.63 billion. EPS of 4 cents beat the&nbsp;<a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">analyst consensus estimate of 3 cents</a>. 
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/25/01/42983710/ibm-globant-epam-top-it-bets-for-2025-driven-by-demand-trends-and-margin-expansion-analyst" rel="noreferrer noopener">IBM, Globant, EPAM Top IT Bets For 2025, Driven by Demand Trends And Margin Expansion: Analyst</a>
Adjusted constant currency IT Services segment revenue <a target="_blank" href="https://www.wipro.com/investors/quarterly-results/" rel="noreferrer noopener">decreased by 0.7% Y/Y</a>.
IT Services' operating margin for the quarter was 17.5%, up by 150 bps Y/Y, reaching a twelve-quarter high.&nbsp;
Net income was 33.5 billion rupees ($392.0 million), up 24.5% Y/Y. Operating cash flow was at 49.3 billion rupees ($576.4 million).
Total bookings stood at $3.51 billion, with large deal bookings worth $961 million, up by 6.0% Y/Y.
Interim Dividend: Wipro declared an interim dividend of $0.0701 per ADS, proposing to ramp up the payout percentage from 45%- 50% to 70% or above of the net income.
CEO and managing director Srini Pallia noted that the company has accomplished its highest margins in the past three years in a seasonally weak quarter and closed 17 large deals with a total value of $1 billion.
Q4 Outlook:&nbsp;Wipro expects IT Services business revenue of $2.602 billion–$2.655&nbsp;billion, (-1.0)% to (+1.0)% Q/Q in <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">constant currency terms</a>.&nbsp;
Price Action:&nbsp;WIT stock was up 0.91% at $3.33 premarket at last check Friday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/25/01/42983278/google-stock-boosted-by-ai-growth-cloud-expansion-and-cost-discipline-despite-doj-and-generative-ai-challenges-analyst" target="_blank" rel="noreferrer noopener">Google Stock Boosted By AI Growth, Cloud Expansion, Cost Discipline Despite DOJ And Generative AI Challenges: Analyst</a></li>
</ul>
Photo: Shutterstock

Guidance

Dividends

Wipro Q3 Earnings: 24.5% Profit Jump, IT Services Margins Hit 12-Quarter High, Boosts Interim Dividend Payout to 70%

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the financial sector.
<h3 class="wp-block-heading">Apollo Commercial Real Estate Finance, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARI#NYSE">ARI</a>)</h3>
<ul>
<li>Dividend Yield: 11.15%</li>
<li>Keefe, Bruyette &amp; Woods analyst Jade Rahmani maintained a Market Perform rating and cut the price target from $9 to $8.75 on Jan. 14, 2025. This analyst has an accuracy rate of 69%.</li>
<li>UBS analyst Douglas Harter maintained a Neutral rating and lowered the price target from $10 to $9.5 on Nov. 15, 2024. This analyst has an accuracy rate of 69%.</li>
<li>Recent News: On Oct. 30, the company posted a third-quarter GAAP loss of 69 cents per share.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011725&amp;t=be2bearmibe3na1">ARI news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011725&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="903" height="833" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/17042849/image-118.png" alt="" class="wp-image-738502" style="width:570px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/17042849/image-118.png 903w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/17042849/image-118-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/17042849/image-118-768x708.png 768w" sizes="(max-width: 903px) 100vw, 903px" /></a></figure>
<h3 class="wp-block-heading">Starwood Property Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STWD#NYSE">STWD</a>)</h3>
<ul>
<li>Dividend Yield: 9.97%</li>
<li>Keefe, Bruyette &amp; Woods analyst Jade Rahmani maintained an Outperform rating and cut the price target from $22.5 to $22 on Jan. 14, 2025. This analyst has an accuracy rate of 69%.</li>
<li>UBS analyst Douglas Hartermaintained a Neutral rating and raised the price target from $19.5 to $20 on Nov. 15, 2024. This analyst has an accuracy rate of 69%.</li>
<li>Recent News: On Dec. 17, 2024, Starwood Property Trust upsized and priced $500 million sustainability bond offering at 6.500% due 2030.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011725&amp;t=be2bearmibe3na1">latest STWD news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011725&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="912" height="827" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/17042924/image-119.png" alt="" class="wp-image-738504" style="width:559px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/17042924/image-119.png 912w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/17042924/image-119-300x272.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/17042924/image-119-768x696.png 768w" sizes="(max-width: 912px) 100vw, 912px" /></a></figure>
<h3 class="wp-block-heading">KKR Real Estate Finance Trust Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KREF#NYSE">KREF</a>)</h3>
<ul>
<li>Dividend Yield: 9.54%</li>
<li>Keefe, Bruyette &amp; Woods analyst Jade Rahmanimaintained an Outperform rating and cut the price target from $13 to $12.25 on Jan. 14, 2025. This analyst has an accuracy rate of 69%.</li>
<li>JP Morgan analyst Richard Shane maintained an Overweight rating and cut the price target from $12 to $11.5 on Dec. 9, 2024. This analyst has an accuracy rate of 69%.</li>
<li>Recent News: On Dec. 12, 2024, KKR Real Estate Finance Trust declared a quarterly dividend of 25 cents per share of common stock.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011725&amp;t=be2bearmibe3na1">latest KREF news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011725&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="897" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/17043008/image-120.png" alt="" class="wp-image-738507" style="width:588px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/17043008/image-120.png 897w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/17043008/image-120-300x280.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/17043008/image-120-768x717.png 768w" sizes="(max-width: 897px) 100vw, 897px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43049593/slb-jb-hunt-transport-and-3-stocks-to-watch-heading-into-friday">SLB, J.B. Hunt Transport And 3 Stocks To Watch Heading Into Friday</a></li>
</ul>

Price Target

Analyst Ratings

KREF

STWD

Wall Street's Most Accurate Analysts Spotlight On 3 Financial Stocks With Over 9% Dividend Yields

NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) is experiencing a slight increase in its share price in premarket trading on Friday, as the company is reportedly expected <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">to be included in a major Hong Kong stock index.</a>
This inclusion is anticipated to bring passive investment inflows, which could provide a boost to NIO's stock despite its recent performance challenges, <a target="_blank" href="https://cnevpost.com/2025/01/17/nio-expected-hk-hang-seng-index/" rel="noreferrer noopener">reports </a>CnEV Post.
The Hang Seng Indexes Company Limited will announce the results of its semi-annual review of the Hang Seng family of indexes after market hours on February 21, per the report, which cited&nbsp;Chinese brokerage CICC. The changes will take effect on Monday, March 10.
Read Next: <a target="_blank" href="https://www.benzinga.com/25/01/43027048/blackrock-generates-industry-leading-etf-inflows-of-390-billion-in-2024-here-are-five-ishares-etfs-that-investors-should-look-out-for" rel="noreferrer noopener">BlackRock Generates Industry-Leading ETF Inflows Of $390 Billion In 2024: Here Are Five iShares ETFs That Investors Should Look Out For</a>
The adjustment will include indices such as the Hang Seng Index, Hang Seng China Enterprises Index, Hang Seng Tech Index and Hang Seng Composite Index, the report said, citing analyst Liu Gang&#8217;s team.
Recently, NIO&nbsp;launched its new affordable EV brand Onvo in May. The brand started selling its first vehicle – the Onvo L60 – in late September and since then, Nio&nbsp;<a target="_blank" href="https://www.benzinga.com//node/42909739" rel="noreferrer noopener">sales have been on the rise.</a>
The Onvo L60 is a mid-size electric SUV that starts at 206,900 yuan (~$28,300) with the battery pack included, much lower than Tesla's affordable models Model 3 or Model Y in China.
In September, NIO&nbsp;delivered 832 Onvo L60s despite having only a few selling days.
In October, the first full month of sales, Onvo deliveries rose to 4,319. In November, deliveries rose to 5,082, implying rising demand for the vehicle.
Price Action: NIO shares are trading higher by 1.2% to $4.21 premarket at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43035577/nio-ceo-welcomes-tiktok-users-to-rednote-amid-us-ban-concerns" target="_blank" rel="noreferrer noopener">NIO CEO Welcomes TikTok Users To RedNote Amid US Ban Concerns</a></li>
</ul>
Photo by Sundry Photography on Shutterstock.

Equities

Media

General

What's Going On With Chinese EV Maker NIO Stock Today?

The Q4 earnings report for Webster Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WBS#NYSE">WBS</a>) was released on Friday, January 17, 2025 at 07:30 AM.
Here's what investors need to know about the latest announcement.
<h3>Earnings</h3>
Webster Finl beat estimated earnings by 6.0%, reporting an EPS of $1.43 versus an estimate of $1.35.
Revenue was up $37.45 million from the same period last year.
<h3>Overview of Past Earnings</h3>
In the previous quarter, the company missed on EPS by $0.01, resulting in a 2.0% drop change in the share price the following day.
Here's a look at Webster Finl's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.35</td>
<td>1.34</td>
<td>1.41</td>
<td>1.46</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.34</td>
<td>1.26</td>
<td>1.35</td>
<td>1.46</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>595.17M</td>
<td>589.41M</td>
<td>616.79M</td>
<td>603.11M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>589.88M</td>
<td>572.30M</td>
<td>567.74M</td>
<td>571.02M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Webster Finl <a href="https://www.benzinga.com/quote/WBS/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Webster Finl Q4 Earnings Assessment

The U.S. Food and Drug Administration (FDA) has granted marketing authorization for 20 nicotine pouch products from ZYN, a <a href="https://www.benzinga.com/pressreleases/25/01/b43037438/fda-authorizes-all-zyn-nicotine-pouch-products-currently-marketed-by-swedish-match-in-the-u-s">brand of nicotine products</a> from Philip Morris International Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>). 
The ZYN nicotine pouches, small sachets containing nicotine meant to be placed between the gum and lip, are the first products of their kind to gain FDA approval.
This decision follows an extensive review, confirming that the ZYN nicotine pouches comply with the public health criteria set by the 2009 <a href="https://www.fda.gov/news-events/press-announcements/fda-authorizes-marketing-20-zyn-nicotine-pouch-products-after-extensive-scientific-review#:~:text=Today%2C%20the%20U.S.%20Food%20and,following%20an%20extensive%20scientific%20review.">Family Smoking Prevention and Tobacco Control Act</a>.
These standards assess the risks and benefits of tobacco products, especially concerning the overall population&#8217;s health.
The FDA&#8217;s assessment showed that these products present lower health risks than cigarettes and other smokeless tobacco items such as snus and moist snuff, due to their reduced levels of harmful chemicals. 
FDA specialists noted that these products could be beneficial for adults who fully transition from cigarettes and smokeless tobacco. 
The FDA also observed that, despite the rise in sales of these products in recent years, the likelihood of youth usage remains minimal.
Also Read: <a href="https://www.benzinga.com/news/25/01/43023778/gm-vianode-strike-multi-billion-anode-graphite-supply-deal-details">GM, Vianode Strike Multi-Billion Anode Graphite Supply Deal: Details</a>
The 2024 National Youth Tobacco Survey revealed that just 1.8% of U.S. middle and high school students reported using nicotine pouches.
"It's critical that the manufacturer market these products responsibly to prevent youth use," said director of the FDA's Center for Tobacco Products, Brian King.
Strict rules have been established to guarantee that ZYN nicotine pouch ads are directed solely at adults aged 21 and over.
The FDA also specified further precautions, including restricting mass media advertising and mandating that actors in commercials be at least 35 years old or made to appear that age. 
Additionally, the FDA emphasized that although these products are approved for sale, they are not deemed safe and the agency will keep monitoring their effect on public health.
The approved nicotine pouch products include flavors such as ZYN Chill, ZYN Cinnamon, ZYN Cool Mint and others, each available in 3 mg and 6 mg strengths.
The FDA&#8217;s approval applies solely to these products and does not cover other nicotine pouches or similar items made by ZYN.
The company is not allowed to assert reduced risk claims for these products unless it files a separate application for a modified risk tobacco product.
Price Action: PM shares closed higher by 1.08% at $119.80 on Thursday.
Photo: Shutterstock

ZYN Nicotine Pouches Receive FDA Marketing Approval

President Joe Biden has granted clemency to nearly 2,500 non-violent drug offenders as his last hours in the White House wind down. 
"Today, I am commuting the sentences of nearly 2,500 people convicted of non-violent drug offenses who are serving disproportionately long sentences compared to the sentences they would receive today under current law, policy, and practice," Biden said in a <a href="https://www.whitehouse.gov/briefing-room/statements-releases/2025/01/17/statement-from-president-joe-biden-on-additional-clemency-actions/">statement</a> Friday. "Today's clemency action provides relief for individuals who received lengthy sentences based on discredited distinctions between crack and powder cocaine, as well as outdated sentencing enhancements for drug crimes." 
No word yet as to whether <a href="https://www.benzinga.com/news/legal/24/11/42177984/joe-biden-how-about-pardoning-non-violent-cannabis-prisoners-along-with-those-thanksgiving-turkeys">non-violent cannabis prisoners</a> will be involved in this group of people receiving commutations.
Read Also:<a href="https://www.benzinga.com/government/regulations/25/01/43040086/nra-warns-of-legal-confusion-over-guns-and-cannabis"> NRA Warns Of Legal Confusion Over Guns And Cannabis: Could Fed Ban Expand?</a>
The clemency is expected to benefit federal prisoners who are serving or were convicted of crack cocaine-related crimes, <a href="https://www.npr.org/2025/01/17/g-s1-41788/biden-pardons-commutations-drug-sentences">noted</a> NPR. The White House said these individuals had received sentences that were longer than they would be under today's drug policies and laws.
Biden told USA Today in a Jan. 8 interview that he would likely address sentencing disparities for offenses involving crack cocaine. &#8220;This action is an important step toward righting historic wrongs, correcting sentencing disparities, and providing deserving individuals the opportunity to return to their families and communities after spending far too much time behind bars,&#8221; he told Susan Page.
The Biden administration often criticized President Ronald Reagan's Anti-Drug Abuse Act that led to the arrest and imprisonment of thousands, a vast majority Black people. Due to automatic sentencing requirements, some people spent decades behind bars for possessing crack or cocaine.
Biden <a href="https://www.benzinga.com/24/12/42258387/biden-grants-full-and-unconditional-pardon-to-hunter-i-hope-americans-will-understand">granted a full and unconditional pardon</a> to his son Hunter Biden in early December 2024, drawing criticism from Democrats and Republicans and many in <a href="https://www.benzinga.com/24/12/42346107/critics-urge-biden-to-free-non-violent-pot-offenders-after-pardoning-son">the cannabis community</a>.
Just two weeks after his son's pardon, Biden <a href="https://www.benzinga.com/news/legal/24/12/42466804/biden-commutes-1500-sentences-grants-39-pardons-pot-prisoners-included-marks-single-day-record">commuted the sentences</a> of nearly 1,500 individuals and pardoned 39 others convicted of nonviolent offenses.
Biden has said he would consider additional pardons, <a href="https://www.nytimes.com/2025/01/17/us/politics/biden-commute-sentences-drug-offenders.html">according</a> to the NY Times, which could include preemptive pardons for former elected officials who President-elect Donald &nbsp;Trump has indicated he may target. &nbsp;
Now Read:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/01/43042694/president-trumps-endorsement-represents-a-sea-change-in-cannabis-policy-says-trulieve-ceo-as-advocacy-groups-join-forces">&#8216;President Trump&#8217;s Endorsement Represents A Sea Change In Cannabis Policy,&#8217; Says Trulieve CEO As Advocacy Groups Join Forces</a></li>
</ul>
Photo: Shutterstock

Cannabis

Government

Politics

Biden Commutes Sentences Of Nearly 2,500 Convicted of Non-Violent Drug Offenses, No Mention Of Cannabis Prisoners

Inspira Technologies Oxy BHN Ltd Ordinary Shares

IINN

Inspira Technologies Announced That the Company Is Establishing A Dedicated Production Line For A Crucial Component Of Its Innovative Respiratory Support System In Collaboration With Zriha Medical Ltd

OKLO

Oklo Signs MoU With Rpower To Deploy A Phased Power Model For Data Centers

ServiceNow To Acquire AI Native Conversation Data Analysis Platform Cuein, Terms Not Disclosed

Partnership will drive deployment of edge-enabled technologies in smart commercial buildings while reducing the need for extensive cloud infrastructure
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.veea.com%2F&amp;esheet=54181673&amp;newsitemid=20250117751306&amp;lan=en-US&amp;anchor=Veea+Inc.&amp;index=1&amp;md5=85fc3b7864e30015d4ce61f07ddef34d">Veea Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEEA#NASDAQ">VEEA</a>), a pioneer in edge computing and AI-driven solutions, and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.lynxspring.com&amp;esheet=54181673&amp;newsitemid=20250117751306&amp;lan=en-US&amp;anchor=Lynxspring%2C+Inc.&amp;index=3&amp;md5=0fdee76b2a830501c4c5fe1394fb25bc">Lynxspring, Inc.</a>, a premier manufacturer, developer, and provider of open software and hardware platforms for smarter buildings, smart equipment and device-to-enterprise integration and automation, announced they have partnered to jointly rollout technologies and solutions that simplify data management, improve operational efficiency, and enable real-time decision-making for building owners and operators.
The combined offering leverages Veea's edge computing capabilities alongside Lynxspring's advanced edge-to-cloud building management and data management solutions to create a comprehensive ecosystem for managing smart environments, including buildings, campuses, agriculture, and cities. This integration of edge-to-enterprise technologies normalizes both wired and wireless endpoints, expanding the available dataset to provide greater actionable insights across all market use cases.

VEEA

Veea and Lynxspring Announce Collaborative Strategic Partnership To Accelerate Edge-To-Cloud And Containerization Opportunities

Barclays analyst Tom O'Malley maintains Western Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) with a Overweight and lowers the price target from $90 to $80.

Barclays Maintains Overweight on Western Digital, Lowers Price Target to $80

Macro Economic Events

Econ #s

Economics

USA Housing Starts For December 1.499M Vs 1.330M Est.; 1.289M Prior (Revised To 1.294M)

<a href="https://www.benzinga.com/news/24/12/42499868/zillows-top-trends-for-homes-in-2025">Zillow </a>has made its much-anticipated prediction for the hottest housing market of 2025. It's <a href="https://www.benzinga.com/real-estate/24/01/36580130/winter-chills-to-housing-thrills-buffalos-surprising-surge-as-the-hottest-real-estate-market-of-2024">Buffalo</a>, New York. That might raise a few eyebrows – as the snowy New York City on the Canadian border experienced years of unemployment and urban dereliction barely a decade ago. However, this marks the second year in a row that Buffalo has taken Zillow's top honor. So what gives?&nbsp;
<h2 class="wp-block-heading">Affordability And Jobs</h2>
Affordability is the root of Buffalo's ascendancy, backed by a deluge of new jobs, which means the once unglamorous industrial city is attracting hordes of new residents. As Zillow explains:&nbsp;
Don't Miss:
<ul>
<li>CEO of Integris gathered a team of senior investment managers who have $34.22 billion in combined owned and managed assets in the West Coast —<a href="https://www.benzinga.com/money/integris"> here&#8217;s how to invest in their private credit fund that targets 12% annual interest rate.</a></li>
<li>Unlock the hidden potential of commercial real estate —<a href="https://equitymultiple.com/benzinga?invite=benzinga&amp;utm_campaign=product-promotion-earn&amp;utm_source=yahooFinance&amp;utm_medium=affiliate&amp;utm_content=unlockboost-yahoo"> This platform allows individuals to invest in commercial real estate offering a 12% target yield with a bonus 1% return boost today!</a></li>
</ul>
"Buffalo has the most new jobs per new home permitted." New jobs and owner-occupied homes have allowed Buffalo to finally shake off its image as a desolate urban wasteland lacking in jobs and culture. According to the NAIOP Commercial Real Estate Development Association, from 2018-2023, an estimated $22.6 billion of development was launched within the eight counties in the Buffalo Niagara region. New investment in medical, manufacturing and a clean energy cluster expansion caused increased numbers of residential real estate, hotels, industrial plants and food processing facilities.
<h2 class="wp-block-heading">Incentives And Revitalization</h2>
Buffalo's renaissance began in 2012 when – according to The New York Times–New York's then-governor andrew M. Cuomo, pledged $1 billion in grants and tax credits as part of a revitalization effort. The residential boom has developed new apartments in empty warehouses, former municipal buildings and longtime parking lots.&nbsp;
See Also: This Jeff Bezos-backed startup will allow you to <a href="https://arrivedhomes.go2cloud.org/aff_c?offer_id=15&amp;aff_id=1006&amp;aff_sub=yahoo&amp;aff_sub2=byerscta100">become a landlord in just 10 minutes, with minimum investments as low as $100 for properties like the Byer House from Stranger Things.</a>
<h2 class="wp-block-heading">Tesla's Bold Ambition</h2>
Not every investment turned out the way New York would have hoped. According to the Wall Street Journal, the state spent nearly $1 billion on <a href="https://www.benzinga.com/markets/equities/25/01/42938578/jamie-dimon-calls-elon-musk-an-extraordinary-talent-jp-morgan-ceo-shares-why-trumps-election-victory-didnt-surprise-him">Elon Musk'</a>s ambitious plan to house the largest solar-panel factory in the Western Hemisphere – a quarter-mile-long facility with 1.2 million square feet of industrial space turning out enough solar-panel shingles to cover 1,000 roofs each week. It never happened. By 2023, they were averaging 21 installations per week. The state now owns the industrial space and leases it to Tesla. However, the $240 million worth of solar panel manufacturing equipment the state bought was sold at a discount or scrapped. A state comptroller's audit found just 54 cents of economic benefit for every subsidy dollar spent on the factory.
"It was a bad deal," state Sen. Sean Ryan, a Buffalo Democrat, said. "A cautionary tale is you can't give governors too much power to get on the phone with egotistical billionaires."
Despite this, Tesla has been a big investor in Buffalo overall. Jason Connell, a spokesman for the state agency overseeing the project, said, "Tesla has made substantial contributions to the local economy, aligning with the region's overall economic revitalization."
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl-y2"> you can become an investor for $0.80 per share today.</a>
<h2 class="wp-block-heading">Other Buoyant Markets Echo Buffalo's Trajectory</h2>
Other markets on Zillow's list echo Buffalo, where jobs have bolstered affordable housing. Indianapolis, Providence, Hartford and Philadelphia round out the top five. However, only Indianapolis is expected to show equity gains in 2025, as high interest rates limit buyer activity. The other markets in the top 10, St. Louis, Charlotte, Kansas City, Richmond, VA and Salt Lake City, have certain similar traits; they are small cities with their roots in industrial, blue-collar work that have embraced future-proof industries in tech, medicine and education and are generally more affordable than some larger American cities, bringing a younger demographic to town.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Read Next:
<ul>
<li>Commercial real estate has historically outperformed the stock market, and<a href="https://equitymultiple.com/benzinga?invite=benzinga&amp;utm_campaign=product-promotion-earn&amp;utm_source=yahooFinance&amp;utm_medium=affiliate&amp;utm_content=stockmarket-yahoo"> this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!</a></li>
<li><a href="https://www.benzinga.com/go/arrived-private-credit-yf">Arrived Home's Private Credit Fund&#8217;s has historically paid an annualized dividend yield of 8.1%&#x2A;</a>, which provides access to a pool of short-term loans backed by residential real estate with just a $100 minimum.<a href="https://www.benzinga.com/go/arrived-private-credit-yf"> </a></li>
</ul>

Real Estate

Zillow Names Buffalo As The Hottest Real Estate Market Of 2025. Here's Why The Snowy New York City Is Making Headlines

USA Building Permits For December 1.483M Vs 1.460M Est. 1.493M Prior

Needham analyst Ryan MacDonald reiterates Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Buy and maintains $270 price target.

Reiteration

VEEV

Needham Reiterates Buy on Veeva Systems, Maintains $270 Price Target

Barclays analyst Tom O'Malley maintains Skyworks Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>) with a Underweight and lowers the price target from $80 to $70.

SWKS

Barclays Maintains Underweight on Skyworks Solutions, Lowers Price Target to $70

Barclays analyst Blayne Curtis maintains Silicon Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLAB#NASDAQ">SLAB</a>) with a Equal-Weight and raises the price target from $75 to $120.

SLAB

Barclays Maintains Equal-Weight on Silicon Laboratories, Raises Price Target to $120

IMAX

NFLX

IMAX Has Entered Into An Agreement With Netflix, Inc. To Debut Oscar-Nominated Director Greta Gerwig's Forthcoming Film "Narnia" Exclusively Across The IMAX Global Theater Network With A Two-Week Run Beginning Thanksgiving 2026.

Duolingo Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>) just delivered another masterclass in keeping learners hooked, and Wall Street is taking notes. Shares <a href="https://www.benzinga.com/quote/DUOL/news">surged as much as 7%</a> on Thursday, and JPMorgan's Bryan M. Smilek sees plenty of upside, reiterating an Overweight rating and a $400 price target.
<h2 class="wp-block-heading">Enter Lily: Video Calls &amp; AI = A Winning Formula</h2>
So, what's driving the rally? Enter Lily, Duolingo's AI sidekick, which can now initiate video calls—not just on iOS but also on Android and five new languages. With Japanese and Korean set to join the mix, Duolingo is tapping deeper into a Google Play-powered revenue stream that accounted for 19% of bookings last quarter. The broader video call rollout, complete with transcripts and expressive animations, isn't just a novelty—it's a calculated move to boost engagement and monetization.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/24/12/42418801/duolingo-and-netflix-bring-squid-game-fans-closer-to-korean-with-new-language-challenge">Duolingo And Netflix Bring Squid Game Fans Closer To Korean with New Language Challenge</a>
Duolingo Max, the company's GenAI-driven premium tier, is also gaining traction. Smilek estimates Max subscriptions will jump from 450,00 in 2024 to 1.37 million in 2025, generating $153 million this year—nearly one-fifth of subscription revenue. A well-timed New Year's campaign offering 20% off Max has further sweetened the deal for language learners looking to level up.
<h2 class="wp-block-heading">US-Based Chinese Learners Surge &#8211; But Why?</h2>
Adding another twist to the story is an unexpected surge in U.S.-based Chinese learners, up 216% year-over-year. Speculation swirls around RedNote, a Chinese learning app some see as a TikTok alternative amid potential U.S. bans. 
However, Smilek isn't buying RedNote as a game-changer for Duolingo. Instead, he points to seasonal trends—New Year's resolutions and the upcoming Chinese New Year on Jan. 29 &#8211; along with Duolingo's own marketing firepower, which has seen impressions rise 80% over the past year.
<h2 class="wp-block-heading">A Strong Growth Trajectory</h2>
With daily active users projected to grow 37% in 2025, Duolingo is proving that when it comes to language learning, engagement is the real currency.
And with AI-driven tutoring gaining steam, Duolingo's $400 price target might just be another milestone in its upward trajectory.
Price Check: Shares of DUOL finished 6.8% higher at $341.80 on Thursday.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43047212/metas-community-notes-to-exempt-paid-ads-leaving-marketers-puzzled-about-organic-content-risks-report">Meta&#8217;s &#8216;Community Notes&#8217; To Exempt Paid Ads, Marketers Left Puzzled About Organic Content Risks: Report</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Asia

Long Ideas

Education

Tech

DUOL

Duolingo's AI-Powered China Surge Impresses Bullish Analyst

WIIM

BMBL

Bumble shares are trading higher after the company announced that Founder and Executive Chair Whitney Wolfe Herd will assume the role of Chief Executive Officer, effective mid-March 2025.

Naz Rahman, an analyst from Maxim Group, maintained the Buy rating on Petros Pharmaceuticals (PTPI – Research Report). The associated price target ...

Buy Rating Justified for Petros Pharmaceuticals Amid AI Integration and Strategic OTC Expansion

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth checking out on Thursday as we break down all of the hottest stock market news this morning!



Moving stocks this morning are clinical trail updates, an earnings report, acquisition news and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Neo-Concept (NASDAQ:<a href="https://investorplace.com/stock-quotes/nci-stock-quote/">NCI</a>) stock is rocketing more than 60% alongside heavy pre-market trading.</li>



<li>Sify Technologies Limited &ndash; Rights&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/sifyr-stock-quote/">SIFYR</a>) shares are soaring over 29% <a href="https://www.nasdaq.com/articles/sify-technologies-sets-ads-rights-delisting-date">before their delisting next week</a>.</li>



<li>Longeveron (NASDAQ:<a href="https://investorplace.com/stock-quotes/lgvn-stock-quote/">LGVN</a>) stock is surging more than 28% <a href="https://investorplace.com/2024/06/why-is-longeveron-lgvn-stock-up-120-today/">with clinical trial news</a>.</li>



<li>Fangdd Network (NASDAQ:<a href="https://investorplace.com/stock-quotes/duo-stock-quote/">DUO</a>) shares are gaining over 24% with strong early morning trading.</li>



<li>Nxu (NASDAQ:<a href="https://investorplace.com/stock-quotes/nxu-stock-quote/">NXU</a>) stock is increasing more than 17% on heavy early morning trading.</li>



<li>Sequans Communications (NYSE:<a href="https://investorplace.com/stock-quotes/sqns-stock-quote/">SQNS</a>) shares are rising over 16% today.</li>



<li>Broadcom (NASDAQ:<a href="https://investorplace.com/stock-quotes/avgo-stock-quote/">AVGO</a>) stock is heading 13% higher on <a href="https://www.barrons.com/articles/broadcom-stock-split-earnings-0c75392f">Q2 earnings and stock split plans</a>.</li>



<li>Aethlon Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/aemd-stock-quote/">AEMD</a>) shares are climbing more than 11% without any clear news today.</li>



<li>CaliberCos (NASDAQ:<a href="https://investorplace.com/stock-quotes/cwd-stock-quote/">CWD</a>) stock is jumping over 11% this morning.</li>



<li>Roma Green Finance (NASDAQ:<a href="https://investorplace.com/stock-quotes/roma-stock-quote/">ROMA</a>) shares are up more than 10% </li>
</ol><h2>10 Top Losers</h2>



<ol><li>Assure (NASDAQ:<a href="https://investorplace.com/stock-quotes/ionm-stock-quote/">IONM</a>) stock is crashing over 52% after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318390446&amp;type=PDF&amp;symbol=IONM&amp;cdn=e3ce016dbdad608e6e12f639f088590d&amp;companyName=Assure+Holdings+Corp.&amp;formType=425&amp;formDescription=Prospectuses+and+communications%2C+business+combinations&amp;dateFiled=2024-06-12">terminating a merger agreement</a>.</li>



<li>DDC Enterprise (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ddc-stock-quote/">DDC</a>) shares are plummeting more than 28% after <a href="https://www.marketwatch.com/story/ddc-enterprise-shares-surge-after-purchase-of-omsom-2ae3de86?mod=markets">rallying yesterday on an acquisition</a>.</li>



<li>Cara Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cara-stock-quote/">CARA</a>) stock is diving over 20% alongside <a href="https://www.nasdaq.com/press-release/cara-therapeutics-announces-outcome-part-kourage-1-study-evaluating-oral">clinical trial results</a>.</li>



<li>Petros Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/ptpi-stock-quote/">PTPI</a>) shares are tumbling more than 18% on Thursday morning.</li>



<li>PainReform (NASDAQ:<a href="https://investorplace.com/stock-quotes/prfx-stock-quote/">PRFX</a>) stock is taking an over 16% beating this morning.</li>



<li>J.Jill (NYSE:<a href="https://investorplace.com/stock-quotes/jill-stock-quote/">JILL</a>) shares are falling more than 16% after <a href="https://www.nasdaq.com/press-release/jjill-announces-pricing-public-offering-common-stock-2024-06-12">pricing a public offering</a>.</li>



<li>EpicQuest Education (NASDAQ:<a href="https://investorplace.com/stock-quotes/eeiq-stock-quote/">EEIQ</a>) stock is dropping over 16% this morning.</li>



<li>Expion360 (NASDAQ:<a href="https://investorplace.com/stock-quotes/xpon-stock-quote/">XPON</a>) shares are decreasing more than 14% today.</li>



<li>KWESST Micro Systems (NASDAQ:<a href="https://investorplace.com/stock-quotes/kwe-stock-quote/">KWE</a>) stock is declining over 12% as it <a href="https://investorplace.com/2024/06/why-is-kwesst-micro-systems-kwe-stock-up-121-today/">comes off a recent rally</a>.</li>



<li>VS Media (NASDAQ:<a href="https://investorplace.com/stock-quotes/vsme-stock-quote/">VSME</a>) shares close out our pre-market stock movers down more than 12%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-june-13th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Petros Pharmaceuticals (PTPI – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Naz Rahma...

Buy Rating Affirmed for Petros Pharmaceuticals Amidst Promising Web App Technology and Strategic Advancements

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Petros Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/ptpi-stock-quote/">PTPI</a>) just reported results for the second quarter of 2024.<ul><li>Petros Pharmaceuticals reported earnings per share of -37 cents. This was above the analyst estimate for EPS of -77 cents.</li><li>The company reported revenue of $1.42 million.</li><li>This was 1.50% better than the analyst estimate for revenue of $1.40 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/ptpi-stock-earnings-petros-pharmaceuticals-for-q2-of-2024/">PTPI Stock Earnings: Petros Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

PTPI Stock Earnings: Petros Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024

Maxim Group analyst Naz Rahman reiterated a Buy rating on Petros Pharmaceuticals (PTPI – Research Report) yesterday. The company's shares closed ye...

Maxim Group Sticks to Its Buy Rating for Petros Pharmaceuticals (PTPI)

Analyst Naz Rahman from Maxim Group reiterated a Buy rating on Petros Pharmaceuticals (PTPI – Research Report) and decreased the price target to $1...

Positive App Study Outcomes Enhance Prospects for Petros Pharmaceuticals' OTC Stendra

The latest update is out from Petros Pharmaceuticals ( ($PTPI) ). John Shulman and Greg Bradley, both members of the board of directors at Petros P...

Board Reshuffle at Petros Pharmaceuticals Following Resignations

An update from Petros Pharmaceuticals ( ($PTPI) ) is now available. Petros Pharmaceuticals has amended its employment agreement with President Fady...

Petros Pharmaceuticals Amends President's Employment Terms

Petros Pharmaceuticals (PTPI) announces a shift in its corporate strategy to focus on the development of its proprietary technology platform as a p...

Petros to shift focus to development of tech as Rx-to-OTC switch solution

Petros Pharmaceuticals (PTPI) announces its conducive position in connection with the recently issued final rule, "Nonprescription Drug Product wit...

Petros announces 'conducive position' with newly approved FDA OTC final rules

AVGO

CARA

EEIQ

IONM

JILL

LGVN

PRFX

ROMA

SIFYR

SQNS

VSME

XPON

Biotech

Press Releases

Petros Pharmaceuticals Launches U.S. Distribution of Prescription ED Medication STENDRA Through Recently Announced Collaboration With Lemonaid Health, a Subsidiary of 23andMe

Petros Pharmaceuticals Activates Advisory Committee to Help Guide Rx-to-OTC Switch for STENDRA

Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA(R) (avanafil) OTC Switch

Petros Pharmaceuticals' STENDRA(R) (avanafil) Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance

Petros Pharmaceuticals' Pivotal Statistically Significant Self Selection Study Shows Stronger Results with Proprietary Technology Application as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)

Events

Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)

Proprietary Technology Addressing the Rx-to-OTC Switch Self-Care Market Valued at over $38 Billion annually

Petros Pharmaceuticals Featured in "New Era of Healthcare, AI, Data and Consumer Empowerment"

Petros Pharmaceuticals Strategically Positioned to Benefit as Technology Leader from Newly Approved FDA OTC Final Rules

Comments

Petros Pharma

Noticias

Últimas noticias sobre Petros Pharma (NASDAQ:PTPI) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL